Read by QxMD icon Read

cisplatin adriamycin

Bi-Yuan Hu, Yun-Hao Gu, Chen-Jie Cao, Jun Wang, Dong-Dong Han, Ying-Chao Tang, Hua-Sheng Chen, Aihua Xu
The aim of the present study was to investigate the reversal effect and its related mechanism of Ginkgo biloba exocarp extracts (GBEEs) in obtained multidrug resistance (MDR) of mice S180 tumor cells in vitro and in vivo. In order to simulate the clinical PFC [cis-dichlorodiamineplatinum, cisplatin (DDP) + fluorouracil (FU), FU+cyclophosphamide and cyclophosphamide] scheme, a gradually increasing dose was administered in a phased induction in order to induce S180 cells in vivo and to make them obtain multidrug resistance...
October 2016: Experimental and Therapeutic Medicine
Qun Fang, XiaoYan Chen, XuTing Zhi
BACKGROUND In this study, we aimed to investigate the association between UCA1 and miR-27b in gastric cancer and further study their involvement in multi-drug resistance (MDR) of gastric cancer. MATERIAL AND METHODS The microarray data of dysregulated lncRNAs in gastric cancer tissues was retrieved in the GEO dataset. QRT-PCR analysis was performed to assess UCA1 expression based on 28 paired cancerous and peritumoral normal tissues. The human gastric cancer cell line SGC-7901, and SGC-7901 derived Adriamycin (doxorubicin) resistant SGC-7901/ADR, cisplatin resistant SGC-7901/DDP, and 5-FU resistant SGC-7901/FU cells were used as in vitro cell models to assess the effect of UCA1 and miR-27b on MDR...
October 1, 2016: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
M Yamasaki, T Yasuda, M Yano, M Hirao, K Kobayashi, K Fujitani, S Tamura, Y Kimura, H Miyata, M Motoori, O Shiraishi, T Makino, T Satoh, M Mori, Y Doki
BACKGROUND: This phase II trial evaluated the efficacy of cisplatin and fluorouracil (CF)-based combination neoadjuvant chemotherapy on the outcome of patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC). We compared the recurrence-free survival (RFS) associated with CF plus Adriamycin (ACF) with that associated with CF plus docetaxel (DCF) to select an alternative regimen in a new phase III trial investigating the optimal neoadjuvant treatment for patients with ESCC...
September 29, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Hanqing Chen, Zhengpeng Shi, Bing Gao, Fengqing Fu, Xueguang Zhang
Objective To investigate the expression and biological significance of costimulatory molecule B7-H6, a member of B7 family, in glioma stem like cells (GSLCs). Methods In virtue of the ability of forming neurospheres in vitro , GSLCs were isolated from U87 cells by cell sub-cloning. Real-time quantitative PCR and flow cytometry were performed to detect the expressions of stem cell related markers (c-myc, Sox2, CD133, nestin, and CXCR4), as well as the expressions of B7 family molecules. The different doses of adriamycin, carboplatin, cisplatin, were used to treat GSLCs for testing their chemotherapy-resistance...
September 2016: Xi Bao Yu Fen Zi Mian Yi Xue za Zhi, Chinese Journal of Cellular and Molecular Immunology
Jinxiang Huang, Fenglin Zhang, Lei Jiang, Guohan Hu, Wei Sun, Chenran Zhang, Xuehua Ding
Purpose: Prolactinoma (prolactin-secreting pituitary adenoma) is one of the most common estrogen-related functional pituitary tumors. As an agonist of the dopamine D2 receptor, Bromocriptine is used widely to inhibit prolactinoma progression. On the other hand, it is not always effective in clinical application. Although a dopamine D2 receptor deficiency contributes to the impaired efficiency of bromocriptine therapy to some extent, it is unknown whether there some other underlying mechanisms leading to bromocriptine resistance in prolactinoma treatment...
July 28, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
Yoshiyuki Matsui, Osamu Ogawa, Ryutaro Ishitsuka, Jun Miyazaki, Takamitsu Inoue, Susumu Kageyama, Mikio Sugimoto, Koji Mitsuzuka, Yusuke Shiraishi, Hidefumi Kinoshita, Hironobu Wakeda, Takeshi Nomoto, Eiji Kikuchi, Keiko Fujie, Naoto Keino, Hiroyuki Nishiyama
BACKGROUND: The standard regimen of systemic chemotherapy for patients with advanced urothelial cancer (UC) changed from methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) to gemcitabine and cisplatin (GC) in 2008 when the use of gemcitabine for UC began to be reimbursed by public health insurance in Japan. We examined its influence on the chemotherapy trend in elderly patients aged ≥80 years. METHODS: Among 345 patients included in our previous multicenter retrospective cohort study (chemotherapy for urothelial carcinoma: renal function and efficacy study; CURE study), the outcome of 30 patients aged ≥80 years was reviewed before and after 2008 and compared with 315 young patients...
June 27, 2016: International Journal of Clinical Oncology
Ewa Krasuska-Sławińska, Agnieszka Brożyna, Bożenna Dembowska-Bagińska, Dorota Olczak-Kowalczyk
AIM OF THE STUDY: To determine reasons for the increase in caries among children/adolescents treated for neoplasms. MATERIAL AND METHODS: Health promoting behaviour, oral hygiene (PLI), gingiva (GI), dentition (DMFt/DMFs), number of teeth with white spot lesions (WSL), and enamel defects (ED) were assessed in three groups of 60 patients each. The three groups were as follows: under chemotherapy (CH), after chemotherapy (PCH), and generally healthy (CG). Medical files supplied information on neoplasm type, chemotherapeutic type and dose, age at treatment start, chemotherapy duration, and complications...
2016: Contemporary Oncology Współczesna Onkologia
Lingling Xu, Wei Guo, Ying Liu, Xueqing Zhang, Juntao Yu, Wencai Wu, Tiejun Zhao
Chemotherapy as a routine method for clinical treatment of cancer has disadvantages such as significant toxicity and strong resistance. In order to improve the efficacy of the drugs and reduce the by-effects, we tried to combine static magnetic field (SMF) with cisplatin or adriamycin. The growth of Hepa1-6 cells treated with the static magnetic field (SMF) combined with cisplatin or adriamycin was significantly inhibited, as detected with MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide) test...
September 2015: Sheng Wu Gong Cheng Xue Bao, Chinese Journal of Biotechnology
Shuo Zhang, Yong Zhang, Yong-Hua Yu, Jia Li
Desmoplastic small round cell tumor (DSRCT) is a rare tumor that mainly affects adolescents, and typically involves the abdominal and pelvic peritoneum. The present study reports one case of giant DSRCT, treated with concurrent chemoradiotherapy, and reviews the available medical literature. A 38-year-old man presented with a 3-month history of pain in the left lower abdomen and nausea, associated with decreased appetite and weight loss. Computed tomography (CT) showed a 12.3×7.9 cm confluent solid mass in the lower abdomen and pelvic cavity...
February 2016: Oncology Letters
Malgorzata Wojcik, Anna Kalicka-Kasperczyk, Teresa Luszawska-Kutrzeba, Walentyna Balwierz, Jerzy B Starzyk
Cushing syndrome due to ectopic secretion of ACTH in infants is rare. The treatment of choice is radical resection of the tumour in combination with pre-operative chemotherapy using steroidogenesis inhibitors if necessary. If radical surgery is not possible, palliative treatment of hypercortisolemia is recommended. The most frequently used drug in infants is ketoconazole. Experience with the use of metyrapone is poor. We report an 8-month-old female infant with congenital immature sacrococcygeal teratoma secreting AFP, beta hCG and ACTH who had undergone non-radical resection of the tumour mass and was receiving standard risk chemotherapy (vinblastine, bleomycin, and cisplatin)...
December 2015: Neuro Endocrinology Letters
Ying Zhang, Jin Wang, Qiao-dan Zhou, Cong-hui Zhang, Qing Li, Shuai Huang, Juan Zhan, Kun Wang, Yan-yan Liu, Gang Xu
Renal tubulointerstitial fibrosis is the common ending of progressive renal disease. It is worth developing new ways to stop the progress of renal fibrosis. Peroxisome proliferator-activated receptor-γ (PPARγ) agonists have been studied to treat diabetic nephropathy, cisplatin-induced acute renal injury, ischemia reperfusion injury and adriamycin nephropathy. In this study, unilateral ureteral obstruction (UUO) was used to establish a different renal fibrosis model. PPAR? agonist pioglitazone was administrated by oral gavage and saline was used as control...
February 2016: Journal of Huazhong University of Science and Technology. Medical Sciences
Eiji Kikuchi, Jun Miyazaki, Kazuyuki Yuge, Masayuki Hagiwara, Daishi Ichioka, Takamitsu Inoue, Susumu Kageyama, Mikio Sugimoto, Koji Mitsuzuka, Yoshiyuki Matsui, Shingo Yamamoto, Hidefumi Kinoshita, Hironobu Wakeda, Kazuya Hanai, Hiroyuki Nishiyama
OBJECTIVE: There has been no clear evidence supporting similar chemo-responses for upper and lower urothelial carcinomas. METHODS: We conducted a multicenter retrospective cohort study to analyze urothelial carcinoma patients who underwent systemic chemotherapy at 17 centers from 2004 to 2010. A total of 298 patients with either urothelial carcinoma of the bladder (N = 151) or upper tract urothelial carcinoma (N = 147) were included. Differences in tumor location (urothelial carcinoma of the bladder vs...
February 2016: Japanese Journal of Clinical Oncology
Ki Hong Kim, Sung Joon Hong, Kyung Seok Han
BACKGROUND: Platinum-based systemic chemotherapy is the treatment of choice for patients with advanced urothelial carcinoma (UC). Although no chemotherapeutic regimen is established as a second-line therapy, recent studies reported that methotrexate, vinblastine, Adriamycin and cisplatin (MVAC) elicited a significant response in patients who failed gemcitabine and platinum (GP) chemotherapy. We investigated the clinical factors useful for predicting a favourable response to MVAC in UC patients who failed GP...
2015: BMC Cancer
Hyung Suk Kim, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku
PURPOSE: To systematically assess and compare the relationship between various neoadjuvant chemotherapy regimens and pCR in patients with muscle-invasive bladder cancer. EXPERIMENTAL DESIGN: We performed a literature search of PubMed, Embase, and the Cochrane Library for all articles published before March 2015 and according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. There were 17 articles that met the study eligibility criteria and were selected for the final analysis...
March 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Gamze Bildik, Nazlı Akin, Filiz Senbabaoglu, Gizem Nur Sahin, Sercin Karahuseyinoglu, Umit Ince, Cagatay Taskiran, Ugur Selek, Kayhan Yakin, Yilmaz Guzel, Cem Ayhan, Ebru Alper, Mustafa Cetiner, Basak Balaban, Nil Molinas Mandel, Tarık Esen, Akira Iwase, Bulent Urman, Ozgur Oktem
STUDY QUESTION: Is there any in vitro evidence for or against ovarian protection by co-administration of a GnRH agonist with chemotherapy in human? SUMMARY ANSWER: The co-administration of GnRH agonist leuprolide acetate with cytotoxic chemotherapy agents does not preserve ovarian reserve in vitro. WHAT IS KNOWN ALREADY: Randomized controlled trials of the co-administration of gonadotrophin-releasing hormone (GnRH) agonists with adjuvant chemotherapy to preserve ovarian function have shown contradictory results...
December 2015: Human Reproduction
Zoltán V Varga, Peter Ferdinandy, Lucas Liaudet, Pál Pacher
Mitochondria has an essential role in myocardial tissue homeostasis; thus deterioration in mitochondrial function eventually leads to cardiomyocyte and endothelial cell death and consequent cardiovascular dysfunction. Several chemical compounds and drugs have been known to directly or indirectly modulate cardiac mitochondrial function, which can account both for the toxicological and pharmacological properties of these substances. In many cases, toxicity problems appear only in the presence of additional cardiovascular disease conditions or develop months/years following the exposure, making the diagnosis difficult...
November 2015: American Journal of Physiology. Heart and Circulatory Physiology
Kamran Zargar-Shoshtari, Homayoun Zargar, Colin P Dinney, Cesar E Ercole, Pranav Sharma, Evan Kovac, Petros D Grivas, Andrew J Stephenson, Jay B Shah, Peter C Black, Philippe E Spiess
PURPOSE: Several disease characteristics have been identified as potential predictors for pathological node involvement (pN+) following radical cystectomy (RC). However, these have not been assessed in patients treated with neoadjuvant chemotherapy (NAC). We endeavored to assess factors predicting adverse pathology in clinically node-negative patients treated with NAC and RC. METHODS: Patients from four North American institutions with cT2-4aN0M0 UC who received three or four cycles of NAC followed by RC were selected...
May 2016: World Journal of Urology
Deniz Koksal, Ferhad Ibrahimov, Meral Bugdayci, Gokhan Gedikoglu, Salih Emri
Rhabdomyosarcoma is an aggressive malignant tumor of childhood, originating from immature cells that are destinated to form striated skeletal muscle. It usually arises in the head and neck or the extremities. Primary diffuse pleural rhabdomyosarcoma is exceptionally rare. Herein we report a case of primary diffuse pleural rhabdomyosarcoma in a 48-year-old man. The diagnosis was confirmed by percutaneous pleural biopsy. Chemotherapy (cisplatin, ifosfamide, adriamycin, vincristine) was initiated due to the large volume of the tumor...
January 2016: Asian Cardiovascular & Thoracic Annals
Ping Xu, Yong-Fang Jiang, Jing-Hua Wang
Sorcin is a penta-EF hand calcium binding protein, which is involved in the resistance to chemotherapeutics in cancer cells, and is overexpressed in various cancer cells. However, tumor relapse combined with the development of drug resistance remains a significant problem. Here, we demonstrated that silencing of Sorcin in chemotherapy resistance myeloma U266/ADM and KM3/DDP cell lines resulted in reduced cell proliferation, cell cycle arrest and cell apoptosis. Sorcin siRNA successfully silenced Sorcin mRNA and protein expression...
2015: International Journal of Clinical and Experimental Pathology
Ruiguang Zhang, Yan Li, Zhongliang Wang, Lingjuan Chen, Xiaorong Dong, Xiu Nie
Non-small cell lung cancer is commonly seen with higher morbidity and mortality. High-mobility group protein 1 (HMGB1) is a highly conserved nuclear protein, which is involved in multiple human diseases including cancers. However, the mechanisms of HMGB1 in non-small cell lung cancer remain unclear. The goal of the present study is to identify the relationship between HMGB1 and the progresssion of non-small cell lung cancer and investigate the molecular mechanism of HMGB1 in non-small lung cancer cell lines...
November 2015: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"